Last reviewed · How we verify

Treatment of carcinoma in situ (CIS) of the urinary bladder — Treatment Landscape & Competitive Intelligence

Treatment of carcinoma in situ (CIS) of the urinary bladder (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Treatment of carcinoma in situ (CIS) of the urinary bladder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tice Bcg bcg Pfizer Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC] BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 1 drug in Treatment of carcinoma in situ (CIS) of the urinary bladder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Treatment of carcinoma in situ (CIS) of the urinary bladder:

Cite this brief

Drug Landscape (2026). Treatment of carcinoma in situ (CIS) of the urinary bladder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/treatment-of-carcinoma-in-situ-cis-of-the-urinary-bladder. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing